Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease
Table 2
Results of assessed biomarkers in CKD patients and control group.
Biomarkers
CKD patients before treatment
CKD patients after treatment
Control group
() (Me; 25–75%)
() (Me; 25–75%)
() (Me; 25–75%)
IL-1β (pg/mL)
2.78 (2.00–3.36)
2.69 (2.48–3.15)
1.25 (0.89–1.65)
TNF-RI (pg/mL)
4644 (4156–5677)
4979 (4236–6667)
1151 (930–1332)
TNF-RII (pg/mL)
8010 (7298–8689)
9180 (8845–9908)
2351 (1900–2600)
sFasL (pg/mL)
85.9 (68.0–109.9)
94.3 (75.6–103.8)
47.0 (30.5–80.0)
sFas (pg/mL)
3272 (2734–3799)
3206 (2826–3715)
465.0 (368.0–645.0)
sE-selectin (ng/mL)
28.3 (24.2–33.6)
33.5 (26.0–36.2)
15.5 (11.7–22.9)
sICAM-1 (ng/mL)
402.0 (336.0–504.0)
466.0 (355.0–518.0)
242.0 (234.0–272.0)
TIMP-1 (ng/mL)
203.0 (186.5–258.5)
212.0 (178.0–228.0)
110.0 (91.0–131.0)
sVCAM-1 (ng/mL)
2380 (1326–2790)
2600 (1720–4129)
840.0 (760.0–1252.0)
MMP-9 (ng/mL)
1062 (665–1455)
586.0 (450.0–764.0)
280.0 (217.0–292.0)
TGF-β1 (pg/mL)
21.4 (19.0–30.1)
21.2 (16.5–29.3)
11.6 (9.7–15.5)
versus control group; versus CKD patients before treatment. CKD = chronic kidney disease, (Me; 25–75%) = median and interquartile range, IL-1β = interleukin 1β, TNF-RI = soluble tumor necrosis factor receptor I, TNF-RII = soluble tumor necrosis factor receptor II, sFasL = soluble Fas ligand, sFas = soluble Fas, sICAM-1 = soluble intercellular adhesion molecule-1, TIMP-1 = tissue inhibitor of metalloproteinase-1, sVCAM-1 = soluble human vascular cell adhesion molecule-1, MMP-9 = metalloproteinase-9, and TGF-β1 = transforming growth factor-beta 1.
